PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Clinical trials for PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS trials appear
Sign up with your email to follow new studies for PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a simple sugar powder help save kidneys? new trial underway for FSGS
Disease control Recruiting nowThis phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if t…
Matched conditions: PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New pill aims to slow kidney damage in FSGS patients
Disease control Recruiting nowThis study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…
Matched conditions: PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare kidney diseases: three drugs enter trial
Disease control Recruiting nowThis study tests three experimental drugs—frexalimab, brivekimig, and rilzabrutinib—in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine, a key sign of kidney damage, and help patients achieve remis…
Matched conditions: PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to slow kidney damage in diabetes and rare diseases
Disease control Recruiting nowThis study tests an experimental drug called WAL0921 in 96 adults with kidney diseases that cause protein in the urine, including diabetic nephropathy and several rare conditions. Participants receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks, th…
Matched conditions: PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Walden Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC